CD8A and neoplasm: Indeed, depletion of NK1.1+ cells and CD8+ cells abrogates the therapeutic efficacy (Supplementary Fig. 5A–D), demonstrating ZD55-IL-24 can activate the tumor-infiltrating NK cells and CD8+ T cells, which then kill the tumor cells.